Cambrooke Therapeutics

Boston, United States Founded: 2000 • Age: 26 yrs Acquired By Ajinomoto Health & Nutrition North America
Specialized medical nutrition formulas are developed and manufactured.

About Cambrooke Therapeutics

Cambrooke Therapeutics is a company based in Boston (United States) founded in 2000 was acquired by Ajinomoto Health & Nutrition North America in November 2017.. Cambrooke Therapeutics has raised $17.28 million across 5 funding rounds from investors including Seventure Partners, Galen Partners and Ajinomoto Health & Nutrition North America. Cambrooke Therapeutics has completed 1 acquisition, including Nualtra. Cambrooke Therapeutics offers products and services including Glytactin and KetoVie.

  • Headquarter Boston, United States
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Ajinomoto Cambrooke, Inc
Operational Areas
Healthcare → Nutrition, Wellness & Lifestyle Health
Key Metrics
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Cambrooke Therapeutics

Cambrooke Therapeutics offers a comprehensive portfolio of products and services, including Glytactin and KetoVie. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Glytactin is utilized for managing PKU and other metabolic conditions, as it is designed to provide essential nutrients without increasing protein intake.

KetoVie is employed in ketogenic diets for epilepsy and related disorders, as it is formulated to simplify daily nutritional management.

People of Cambrooke Therapeutics
Headcount 50-200
Employee Profiles 16
Employee Profiles
People
Panayiotis Charalambous
Vice President, International Operations
People
Dan Torrice
Sr. Client Services Specialist - Severe Protein Allergy & ENU Nutrition
People
Emily Sue Orrick Rdn, Ld
Regional Account Manager
People
Howard Lossing
Chief Executive Officer and President

Unlock access to complete

Funding Insights of Cambrooke Therapeutics

Cambrooke Therapeutics has successfully raised a total of $17.28M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 5
  • Last Round
  • First Round

    (11 Jun 2010)

  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
Apr, 2016 Amount Series C - Cambrooke Therapeutics Valuation

investors

Jan, 2016 Amount Unspecified - Cambrooke Therapeutics Valuation

investors

Jan, 2013 Amount Grant - Cambrooke Therapeutics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Cambrooke Therapeutics

Cambrooke Therapeutics has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Seventure Partners, Galen Partners and Ajinomoto Health & Nutrition North America. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
Tech & Life Sciences focused stage agnostic VC firm investing in Europe, Asia & the US
Founded Year Domain Location
PE firm investing in the US
Founded Year Domain Location
-
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Cambrooke Therapeutics

Cambrooke Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Nualtra. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Proprietary medical nutrition products are manufactured and marketed.
2012
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Cambrooke Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Cambrooke Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Cambrooke Therapeutics

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Cambrooke Therapeutics

Frequently Asked Questions about Cambrooke Therapeutics

When was Cambrooke Therapeutics founded?

Cambrooke Therapeutics was founded in 2000 and raised its 1st funding round 10 years after it was founded.

Where is Cambrooke Therapeutics located?

Cambrooke Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.

Is Cambrooke Therapeutics a funded company?

Cambrooke Therapeutics is a funded company, having raised a total of $17.28M across 5 funding rounds to date. The company's 1st funding round was a Grant of $64.4K, raised on Jun 11, 2010.

What does Cambrooke Therapeutics do?

Cambrooke Therapeutics was founded in 2000 in Boston, United States. Operations focus on the medical nutrition sector, where nutritional therapies are developed, manufactured, and commercialized for conditions including metabolic disorders, low-protein diets, and ketogenic needs. Products such as ready-to-drink formulas and powders are offered to meet patient requirements. Support services are extended to patients and healthcare professionals.

What products or services does Cambrooke Therapeutics offer?

Cambrooke Therapeutics offers Glytactin and KetoVie.

How many acquisitions has Cambrooke Therapeutics made?

Cambrooke Therapeutics has made 1 acquisition, including Nualtra.

Who are Cambrooke Therapeutics's investors?

Cambrooke Therapeutics has 3 investors. Key investors include Seventure Partners, Galen Partners, and Ajinomoto Health & Nutrition North America.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available